Терапевтический лекарственный мониторинг кветиапина при терапии шизофрении

The aim was to analyze data of a therapeutic drug monitoring of quetiapine.Material: blood samples (41 samples in the whole) were received from 35 in-patients treated for various forms of schizophrenia. A method of a high performance liquid chromatography with mass-spectrometric detection was used for quantitative determination of quetiapine in the blood. Every patient got an individual outpatient card of monitoring that contained necessary clinical information. The obtained data of quetiapine level were distributed in the following way: 75,6% were in the therapeutic, 4,9% in sub-therapeutic (< 10 ng/mL) and 19,5% conditionally toxic range (> 600 ng/mL), for administration quetiapine at doses of 50 to 1200 mg per day. Two cases of alleged noncompliance were revealed. Distribution on the concentration of quetiapine-wells, normalized for dose administration, shows normal level with a slight asymmetry towards high values. During the analysis we have discovered that the average concentration of quetiapine administered in combination with clozapine was higher than with monotherapy, this should be taken into account by clinicians during correction of the therapy. There was no significant effect of co-medication haloperidol onconcentration of quetiapine.Conclusions: the type of connection between the concentration of quetiapine, concomitant therapy and dose of the drug was revealed as important element of patient-centered treatment technology.

шизофрения, терапевтический лекарственный мониторинг (ТЛМ), высокоэффективная жидкостная хроматография, тандемная хроматомасс-спектрометрия, кветиапин, schizophrenia, therapeutic drug monitoring, high performance liquid chromatography, tandem spectrometry, quetiapine

1. Смулевич А.Б., Козырев В.Н., Андрющенко А.В., Зеленина Е.В., Бескова Д.А., Романов Д.В. Практика стационарной терапии психотических состояний кветиапином (сероквелем) по итогам программы «Наследие» (ретроспективное натуралистическое исследование). Социальная и клиническая психиатрия. 2009;19(4):47-60

2. Brett J. Concerns about quetiapine. Australian prescriber. 2015;38(3):95. PMID:26648630

3. Andrade C. Antipsychotic drugs in schizophrenia: relative effects in patients with and without treatment resistance. J. Clin. Psychiatry. 2016;77(12):1656-1660. doi: 10.4088/ JCP.16f11328

4. Мирошниченко И.И. Рациональное дозирование и мониторинг лекарственных средств. М.: Медицинское информационное агентство, 2011. 416 с

5. Li K.-Y., Cheng Z.-N., Li X., Bai X.-K., Zhang B.-K., Wang F., Li H.-D. Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatographic-electrospray ionization mass spectrome- try. Acta Pharmacol. Sin. 2004;25(1):110-114

6. Mauri M.C., Paletta S., Maffini M., Colasanti A., Dragogna F., Di Pace C., Altamura A.C. Clinical pharmacology of atypical antipsychotics: an update. EXCLI journal. 2014;13:1163

7. Grimm S.W., Richtand N.M., Winter H.R., Stams K.R., Reele S.B. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Brit- ish journal of clinical pharmacology. 2006;61(1):58-69. doi: 10.1111/j.1365-2125.2005.02507.x

8. Mathews M., Muzina D.J. Atypical antipsychotics: new drugs, new challenges. Cleveland Clinic journal of medicine. 2007; 74(8):597-606

9. Abib Jr.E., Duarte L.F., Suenaga E.M., de Carvalho Cruz A., Na- kaie C.R. Comparative bioavailability of two Quetiapine for- mulations in healthy volunteers after a single dose admin- istration. J. Bioequiv. Availab. 2011;3:178-181. doi: 10.4172/ jbb.1000081

10. Baimeeva N.V., Miroshnichenko I.I. Analytical Methods for the Determination of Atypical Neuroleptics (Review). Pharmaceutical Chemistry Journal. 2016;50(5):339-345. doi: 10.1007/s11094-016-1448-4

11. Castberg I., Skogvoll E., Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. The Journal of Clinical Psychiatry. 2007; 68(10):1540-1545